For the Inventor, By the Inventor

Enter assignee name

Oryzon Genomics S.a.

USPTO Granted Patents = 30

CIPO Patents = 17

EPO Patents = 18

Trademarks = 1

Forward Citations = 257

Loading Chart...

Loading Chart...

77 inventors (with patents filed for the assignee):

Alberto Ortega Muñoz (22 out of 22 patents)

Matthew Colin Thor Fyfe (19 out of 19 patents)

Marc Martinell Pedemonte (13 out of 18 patents)

4. Julio Cesar Castro-Palomino Laria (10 out of 16 patents)

5. Nuria Valls Vidal (8 out of 8 patents)

6. Tamara Maes (7 out of 8 patents)

7. Julio Cesar Castro Palomino Laria (7 out of 18 patents)

8. Guido Kurz (6 out of 8 patents)

9. Maria De Los Àngeles Estiarte Martinez (5 out of 5 patents)

10. Jonathan Alleman Baker (4 out of 4 patents)

11. Cristina Mascaro Crusat (3 out of 3 patents)

12. Iñigo Tirapu Fernandez De La Cuesta (3 out of 3 patents)

13. Maria De Los Ángeles Estiarte-Martinez (3 out of 3 patents)

14. Nathalie Guibourt (3 out of 3 patents)

15. Elena Carceller González (2 out of 2 patents)

30 patents: Sort by Forward Citations

1. 12195783 - Methods to determine KDM1A target engagement and chemoprobes useful therefor (2025-01-14),

2. 11034991 - Methods to determine KDM1A target engagement and chemoprobes useful therefor (2021-06-15),

3. 11013698 - Combinations of LSD1 inhibitors for the treatment of hematological malignancies (2021-05-25),

4. 10780081 - Method of treating multiple sclerosis employing a LSD1-inhibitor (2020-09-22),

5. 10329256 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2019-06-25),

6. 10265279 - Combinations of LSD1 inhibitors for use in the treatment of solid tumors (2019-04-23),

7. 10233178 - Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use (2019-03-19),

8. 10221125 - Solid forms (2019-03-05),

9. 10214477 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2019-02-26),

10. 10202330 - Lysine specific demethylase-1 inhibitors and their use (2019-02-12),

11. 9944601 - (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors (2018-04-17),

12. 9908859 - Lysine demethylase inhibitors for myeloproliferative disorders (2018-03-06),

13. 9790196 - Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae (2017-10-17),

14. 9708309 - Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use (2017-07-18),

15. 9676701 - Cyclopropylamine derivatives useful as LSD1 inhibitors (2017-06-13),

Oryzon Genomics S.A. is a clinical stage biopharmaceutical company dedicated to the discovery and development of small molecule epigenetics drugs. Their focus lies in the research and development of potential therapies for diseases such as cancer, neurodegenerative disorders, and autoimmune diseases. Visit their website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

30 Patents

#13 in Madrid

#59 in Spain

#21,168 in the World

Oryzon Genomics S.a.

Forward Citations = 257

77 inventors:

Alberto Ortega Muñoz (22 out of 22 patents)

Matthew Colin Thor Fyfe (19 out of 19 patents)

Marc Martinell Pedemonte (13 out of 18 patents)

4. Julio Cesar Castro-Palomino Laria (10 out of 16 patents)

5. Nuria Valls Vidal (8 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…